A clinical-stage biopharmaceutical company developing psychedelic-based therapies for mental health disorders.
About
AtaiBeckley is a global leader in the development of transformative mental health therapies, formed through the strategic combination of atai Life Sciences and Beckley Psytech in November 2025. The company is dedicated to developing innovative psychedelic-based neuroplastogens and related therapeutics to treat mental health disorders, including treatment-resistant depression and social anxiety disorder.
Tags
Total Employees
95
Current headcount
Performance
Company Timeline
No timeline data for this period
Score Breakdown
67Traction
60Team
30Visibility
37Profile
50Community
15Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does AtaiBeckley do?
AtaiBeckley is a global leader in the development of transformative mental health therapies, formed through the strategic combination of atai Life Sciences and Beckley Psytech in November 2025. The company is dedicated to developing innovative psychedelic-based neuroplastogens and related therapeutics to treat mental health disorders, including treatment-resistant depression and social anxiety disorder.
How much funding has AtaiBeckley raised?
AtaiBeckley has raised a total of $640M in funding. The most recent round on record is Merger.
Where is AtaiBeckley headquartered?
AtaiBeckley is headquartered in New York, United States.
When was AtaiBeckley founded?
AtaiBeckley was founded in 2018.
What industry does AtaiBeckley operate in?
AtaiBeckley operates in Biotech & Life Sciences, MedTech, HealthTech, Drug Discovery, Clinical Trials, Mental Health Tech.
How many employees does AtaiBeckley have?
AtaiBeckley has approximately 95 people on record.